Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective

Area of Science:

• Nuclear Medicine and Molecular Imaging
• Radiopharmaceutical Chemistry
• Precision Medicine

Background:

• Radiopharmaceuticals, biologically active molecules tagged with radionuclides, are crucial for nuclear medicine.
• They facilitate non-invasive diagnostic imaging (PET, SPECT) and targeted radionuclide therapy (β⁻, α, Auger electrons).
• Recent approvals like Copper-64/Copper-67 and Lutetium Lu-177 therapies demonstrate significant clinical progress.

Purpose of the Study:

• To review key innovations in radiopharmaceutical development, including vector design, radionuclide production, and formulation.
• To explore the role of artificial intelligence in enhancing imaging and therapy planning.
• To clarify the evolving regulatory landscape for clinical translation of radiopharmaceuticals.

Main Methods:

• Review of recent advancements in radiopharmaceutical science and clinical applications.
• Analysis of innovations in radionuclide production, bifunctional chelator technology, and vector design.
• Exploration of artificial intelligence applications in nuclear medicine and radioligand therapy planning.

Main Results:

• Highlighting key innovations in vector design, radionuclide production, and formulation strategies.
• Demonstrating the transformative potential of artificial intelligence in optimizing imaging and therapy planning.
• Identifying persistent hurdles in large-scale isotope supply, formulation stability, and regulatory harmonization.

Conclusions:

• Radiopharmaceuticals represent a rapidly advancing field with significant potential for precision imaging and personalized therapy.
• Addressing challenges in production, formulation, and regulation is critical for broader clinical adoption.
• Integrating production, formulation, and regulatory considerations offers a unified path toward improved patient outcomes.